Tenax Therapeutics is trading 5.18% higher at $1.73, alongside gains in biotech and the broader market.
- The biotech sector was up 2.18% during the regular session.
- No clear company-specific catalyst has been identified. An October 27 class-action announcement concerns allegations related to earlier disclosures and the LEVEL trial; available reporting does not establish that it drove this session’s gain.